RT @StephenVLiu: Cabozantinib is a TKI with activity at AXL. It was already explored in combination with erlotinib to overcome #EGFR TKI re…
36,217 followers
25,004 followers
Cabozantinib is a TKI with activity at AXL. It was already explored in combination with erlotinib to overcome #EGFR TKI resistance, in this phase II study by @ReckampK. Some activity - this strategy may apply to many targets but needs biomarker guidance.
10 followers
@FrontOncology @StephenVLiu great to a see the Phase II Trial of Cabozantinib Plus Erlotinib representing your Section of the journal! https://t.co/djQqzfduTN
84 followers
RT @gantaisaku1105: 《短報》 【EGFR陽性肺がん:二次治療】EGFR-TKI後に病勢が進行した人に「カボザンチニブ+タルセバ」併用療法を行った結果、PR 11%、SD 60%、PFS 3.6ヵ月だった。〔Front Oncol〕 https://t.co/…